X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (32539) 32539
Newspaper Article (422) 422
Book Chapter (163) 163
Newsletter (130) 130
Book / eBook (20) 20
Magazine Article (9) 9
Dissertation (8) 8
Transcript (7) 7
Conference Proceeding (3) 3
Reference (3) 3
Book Review (2) 2
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (20606) 20606
animals (14470) 14470
oncology (8128) 8128
proteins (7953) 7953
cancer (7949) 7949
male (6958) 6958
mice (6547) 6547
female (6434) 6434
pharmacology & pharmacy (6033) 6033
kinases (5926) 5926
apoptosis (5554) 5554
cell line, tumor (4443) 4443
research (4337) 4337
biochemistry & molecular biology (3956) 3956
expression (3637) 3637
cell biology (3631) 3631
tumors (3480) 3480
phosphorylation (3468) 3468
rats (3446) 3446
signal transduction (3355) 3355
analysis (3346) 3346
care and treatment (3310) 3310
antineoplastic agents - pharmacology (3205) 3205
health aspects (3178) 3178
chemotherapy (3103) 3103
gene expression (3054) 3054
activation (2873) 2873
medicine (2754) 2754
antineoplastic agents - therapeutic use (2752) 2752
middle aged (2715) 2715
research article (2695) 2695
multidisciplinary sciences (2676) 2676
protein kinase inhibitors - pharmacology (2626) 2626
signal transduction - drug effects (2622) 2622
mutation (2610) 2610
apoptosis - drug effects (2555) 2555
pharmacology (2430) 2430
cancer therapies (2428) 2428
pharmacokinetics (2419) 2419
review (2414) 2414
adult (2392) 2392
protein kinase inhibitors - therapeutic use (2384) 2384
dose-response relationship, drug (2352) 2352
in-vitro (2290) 2290
aged (2287) 2287
inhibition (2280) 2280
clinical trials (2234) 2234
rodents (2217) 2217
physiological aspects (2207) 2207
drug therapy (2195) 2195
cell proliferation - drug effects (2167) 2167
neoplasms - drug therapy (2159) 2159
inflammation (2158) 2158
biology (2081) 2081
medicine & public health (2075) 2075
cells (2027) 2027
science (2020) 2020
metabolism (1974) 1974
studies (1939) 1939
inhibitors (1926) 1926
metastasis (1922) 1922
cell cycle (1906) 1906
chemistry, medicinal (1887) 1887
neurosciences (1882) 1882
genetic aspects (1871) 1871
breast cancer (1845) 1845
treatment outcome (1817) 1817
tyrosine (1739) 1739
medical research (1730) 1730
therapy (1728) 1728
oxidative stress (1724) 1724
enzymes (1636) 1636
pharmacology/toxicology (1628) 1628
drugs (1608) 1608
in-vivo (1606) 1606
hematology (1605) 1605
toxicity (1578) 1578
protein kinase inhibitors - pharmacokinetics (1575) 1575
medicine, research & experimental (1572) 1572
cells, cultured (1560) 1560
disease models, animal (1555) 1555
protein (1542) 1542
angiogenesis (1539) 1539
physiology (1503) 1503
xenograft model antitumor assays (1471) 1471
patients (1449) 1449
cytotoxicity (1442) 1442
growth (1421) 1421
leukemia (1418) 1418
ligands (1399) 1399
chemistry, multidisciplinary (1365) 1365
rats, sprague-dawley (1352) 1352
cell proliferation (1344) 1344
protein binding (1339) 1339
antineoplastic agents - pharmacokinetics (1332) 1332
biochemistry (1327) 1327
cell line (1310) 1310
drug resistance (1298) 1298
resistance (1294) 1294
biomedicine (1291) 1291
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (33264) 33264
Japanese (66) 66
German (51) 51
French (25) 25
Chinese (13) 13
Portuguese (11) 11
Spanish (9) 9
Dutch (8) 8
Norwegian (7) 7
Russian (5) 5
Czech (3) 3
Danish (3) 3
Italian (1) 1
Polish (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Treatment Reviews, ISSN 0305-7372, 2009, Volume 35, Issue 8, pp. 692 - 706
Summary In the recent years, eight tyrosine kinase inhibitors (TKIs) have been approved for cancer treatment and numerous are under investigation... 
Hematology, Oncology and Palliative Medicine | Excretion | Absorption | Metabolism | Tyrosine kinase inhibitors | Distribution | Drug transporters and interactions | CHRONIC MYELOGENOUS LEUKEMIA | RENAL-CELL CARCINOMA | CHRONIC MYELOID-LEUKEMIA | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | CHRONIC MYELOCYTIC-LEUKEMIA | ADVANCED SOLID MALIGNANCIES | IMATINIB MESYLATE GLEEVEC | GASTROINTESTINAL STROMAL TUMORS | CEREBROSPINAL-FLUID PHARMACOKINETICS | CANCER RESISTANCE PROTEIN | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Pyrroles - pharmacokinetics | Humans | Cytochrome P-450 Enzyme System - metabolism | Pyridines - pharmacokinetics | Quinazolines - pharmacokinetics | Biological Availability | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Intestinal Absorption | Thiazoles - pharmacokinetics | Antineoplastic Agents - metabolism | Tissue Distribution | Benzenesulfonates - pharmacokinetics | Drug Interactions | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Piperazines - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Dasatinib | Administration, Oral | Imatinib Mesylate | Protein Kinase Inhibitors - blood | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Agents - blood | Pyrimidines - pharmacokinetics | Indoles - pharmacokinetics | Protein Kinase Inhibitors - pharmacology | Benzamides | Protein Kinase Inhibitors - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Oncology, Experimental | Cytochrome P-450 | Physiological aspects | Phenols | Research | Phosphotransferases | Protein binding | Cancer | Index Medicus
Journal Article
Drug metabolism and disposition, ISSN 1521-009X, 2014, Volume 42, Issue 4, pp. 759 - 773
Journal Article
Cancer discovery, ISSN 2159-8290, 2017, Volume 7, Issue 4, pp. 400 - 409
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including patients... 
REARRANGEMENT | ONCOGENE | ONCOLOGY | ANALOG SECRETORY CARCINOMA | LANDSCAPE | KINASE FUSIONS | SARCOMAS | ETV6-NTRK3 GENE FUSION | CRIZOTINIB | GENOMIC ALTERATIONS | CLINICAL-RESPONSE | Benzamides - pharmacokinetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Receptor, trkA - antagonists & inhibitors | Male | Receptor, trkB - genetics | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Mammary Analogue Secretory Carcinoma - genetics | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Membrane Glycoproteins - antagonists & inhibitors | Receptor, trkC - genetics | Anaplastic Lymphoma Kinase | Melanoma - genetics | Colorectal Neoplasms - drug therapy | Receptor, trkB - antagonists & inhibitors | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Benzamides - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Crizotinib | Protein Kinase Inhibitors - pharmacokinetics | Proto-Oncogene Proteins - antagonists & inhibitors | Pyridines - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Receptor, trkC - antagonists & inhibitors | Melanoma - pathology | Mammary Analogue Secretory Carcinoma - drug therapy | Membrane Glycoproteins - genetics | Protein Kinase Inhibitors - administration & dosage | Sequestosome-1 Protein - genetics | Pyrazoles - administration & dosage | Indazoles - pharmacokinetics | Receptor Protein-Tyrosine Kinases - genetics | Oncogene Proteins, Fusion - genetics | Melanoma - drug therapy | Adolescent | Receptor, trkA - genetics | Oncogene Proteins, Fusion - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Indazoles - adverse effects | Colorectal Neoplasms - pathology | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Journal Article
Nature chemical biology, ISSN 1552-4469, 2015, Volume 11, Issue 7, pp. 525 - 531
Journal Article
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 773 - 781
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
British journal of cancer, ISSN 0007-0920, 02/2019, Volume 120, Issue 3, pp. 286 - 293
BACKGROUND: This phase I, open-label, dose-escalation study evaluated the safety, pharmacokinetics and pharmacodynamics of combination therapy with the HDM2 inhibitor SAR405838 and the MEK1/2 inhibitor... 
Thrombocytopenia/chemically induced | Humans | Middle Aged | Proto-Oncogene Proteins p21(ras)/genetics | Proto-Oncogene Proteins B-raf/genetics | MAP Kinase Kinase Kinases/antagonists & inhibitors | Male | Gene Expression Regulation, Neoplastic/drug effects | Tumor Suppressor Protein p53/genetics | Niacinamide/administration & dosage | Spiro Compounds/administration & dosage | Proto-Oncogene Proteins c-mdm2/antagonists & inhibitors | Dose-Response Relationship, Drug | Indoles/administration & dosage | Protein Kinase Inhibitors/administration & dosage | Maximum Tolerated Dose | Neoplasms/classification | Adult | Female | Aged | Antineoplastic Combined Chemotherapy Protocols/administration & dosage | ACTIVATION | P53 PATHWAY | ONCOLOGY | RG7112 | Niacinamide - analogs & derivatives | Proto-Oncogene Proteins c-mdm2 - genetics | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Proto-Oncogene Proteins p21(ras) - genetics | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Spiro Compounds - administration & dosage | Protein Kinase Inhibitors - adverse effects | Spiro Compounds - adverse effects | Indoles - administration & dosage | Tumor Suppressor Protein p53 - genetics | Neoplasms - genetics | Niacinamide - pharmacokinetics | Gene Expression Regulation, Neoplastic - drug effects | MAP Kinase Kinase Kinases - antagonists & inhibitors | Proto-Oncogene Proteins c-mdm2 - antagonists & inhibitors | Protein Kinase Inhibitors - pharmacokinetics | MAP Kinase Kinase Kinases - genetics | Niacinamide - adverse effects | Neoplasms - classification | Thrombocytopenia - chemically induced | Thrombocytopenia - pathology | Spiro Compounds - pharmacokinetics | Neoplasms - drug therapy | Niacinamide - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Indoles - pharmacokinetics | Neoplasms - pathology | Index Medicus | Targeted therapies | Outcomes research
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 18, pp. 1689 - 1699
...–small-cell lung cancer in whom T790M-mediated drug resistance to other EGFR tyrosine kinase inhibitors had developed... 
MEDICINE, GENERAL & INTERNAL | GEFITINIB | PLACEBO | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | MUTATIONS | AFATINIB | IRREVERSIBLE EGFR | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aniline Compounds - administration & dosage | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Aniline Compounds - pharmacokinetics | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Patient outcomes | Tyrosine | Appetite | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Diarrhea | Nausea | Drug resistance | Kinases | Patients | Epidermal growth factor | Pharmacokinetics | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2013, Volume 49, Issue 16, pp. 3412 - 3419
Abstract Purpose We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC... 
Hematology, Oncology and Palliative Medicine | Second line | Regorafenib | Hepatocellular carcinoma | Tolerability | Safety | Receptor kinase inhibition | Safety Second line | MANAGEMENT | EFFICACY | ONCOLOGY | SUNITINIB | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - mortality | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Female | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacokinetics | Phenylurea Compounds - pharmacokinetics | Liver Neoplasms - enzymology | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Drug Administration Schedule | Europe | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Phenylurea Compounds - therapeutic use | Treatment Outcome | Carcinoma, Hepatocellular - enzymology | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Asia | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Neoplasm Staging | Care and treatment | Safety and security measures | Hepatoma | Index Medicus
Journal Article